ponesimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
immunomodulators, both stimulant/suppressive and stimulant 5446 854107-55-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ponesimod
  • ponvory
  • ACT-128800
Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1. Ponesimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which ponesimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system
  • Molecular weight: 460.97
  • Formula: C23H25ClN2O4S
  • CLOGP: 4.81
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 82.36
  • ALOGS: -4.87
  • ROTB: 8

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
May 19, 2021 EMA Janssen-Cilag International N.V.
March 18, 2021 FDA JANSSEN PHARMACEUTICALS Inc

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA50 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D000081243 Sphingosine 1 Phosphate Receptor Modulators
FDA MoA N0000181815 Sphingosine 1-Phosphate Receptor Modulators
FDA EPC N0000181816 Sphingosine 1-phosphate Receptor Modulator

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Relapsing forms of multiple sclerosis indication 24700007 DOID:2377
Unstable angina contraindication 4557003
Myocardial infarction contraindication 22298006 DOID:5844
Complete atrioventricular block contraindication 27885002
Mobitz type II atrioventricular block contraindication 28189009 DOID:11312
Sick sinus syndrome contraindication 36083008 DOID:13884
Heart failure contraindication 84114007 DOID:6000
Decompensated cardiac failure contraindication 195111005
Cerebrovascular accident contraindication 230690007
Transient ischemic attack contraindication 266257000 DOID:224




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
20MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
2MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
3MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
4MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
5MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
6MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
7MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
8MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
9MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9000018 Nov. 16, 2024 REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
10MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
20MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
2MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
3MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
4MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
5MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
6MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
7MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
8MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
9MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 8273779 Dec. 17, 2025 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
10MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
20MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
2MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
3MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
4MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
5MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
6MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
7MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
8MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
9MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 9062014 May 6, 2032 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS
10MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
20MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
2MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
3MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
4MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
5MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
6MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
7MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
8MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE
9MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL 10220023 Dec. 10, 2035 TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
20MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
2MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
3MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
4MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
5MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
6MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
7MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
8MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY
9MG PONVORY JANSSEN PHARMS N213498 March 18, 2021 RX TABLET ORAL March 18, 2026 NEW CHEMICAL ENTITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sphingosine 1-phosphate receptor 1 GPCR AGONIST EC50 8.13 SCIENTIFIC LITERATURE DRUG LABEL
Sphingosine 1-phosphate receptor 5 GPCR AGONIST EC50 7.23 SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 4 GPCR AGONIST EC50 5.96 SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 3 GPCR AGONIST EC50 6.94 SCIENTIFIC LITERATURE

External reference:

IDSource
D11215 KEGG_DRUG
5G7AKV2MKP UNII
C2934701 UMLSCUI
CHEMBL1096146 ChEMBL_ID
11363176 PUBCHEM_CID
DB12016 DRUGBANK_ID
CHEMBL1095833 ChEMBL_ID
9320 IUPHAR_LIGAND_ID
2532300 RXNORM
344652 MMSL
39406 MMSL
d09723 MMSL
1179253008 SNOMEDCT_US
1179254002 SNOMEDCT_US
4040289 VANDF
018671 NDDF
C550169 MESH_SUPPLEMENTAL_RECORD_UI
9150 INN_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
PONVORY HUMAN PRESCRIPTION DRUG LABEL 1 50458-720 TABLET, FILM COATED 20 mg ORAL NDA 31 sections